This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 19, 2013 /PRNewswire/ --
Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, will hold a conference call on
Wednesday, February 20, 2013, at
4:30 p.m. ET to discuss full results for its fourth quarter and year ended
December 31, 2012.
While previously expecting to report only preliminary results on this date, the company recently received its annual 'true-up' of OVA1 sales from Quest Diagnostics ahead of schedule. This will allow for complete 2012 results to be issued in a press release prior to the call.
Vermillion's interim CEO
Bruce A. Huebner will host the call, followed by a question and answer period.
Wednesday, February 20, 2013Time:
4:30 p.m. Eastern time (
1:30 p.m. Pacific time)Dial-In Number: 1-800-909-4761International: 1-212-231-2934Conference ID#: 21648726Webcast:
The conference call will be webcast live and available for replay via the investor section of the company's website at
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available approximately two hours after the call through
March 6, 2013.
Toll-free replay number: 1-800-633-8284International replay number: 1-402-977-9140Replay pin number: 21648726
About VermillionVermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at
Investor Relations Contact:Liolios Group, Inc.
Ron Both Tel 1-949-574-3860
SOURCE Vermillion, Inc.